WASHINGTON — The United States Food and Drug Administration has approved Gazyva injection to induce remission of proteinuria in adults with primary membranous nephropathy who are at risk of disease progression. The decision establishes the first drug approved specifically for treating adults with the rare autoimmune kidney disorder.
Phase 3 Trial Delivers Superior Proteinuria Remission
The efficacy and safety of Gazyva were evaluated in MAJESTY, a Phase 3, randomized, controlled, open-label, multicenter study in 142 adults with primary membranous nephropathy. During the 104-week evaluation, patients received either Gazyva or off-label tacrolimus. Complete remission of proteinuria required a urine protein-creatinine ratio of no more than 0.3 with stable kidney filtration. The proportion of patients achieving complete remission at week 104 was significantly higher in the Gazyva group at 36% compared to the tacrolimus group at 6%.
Boxed Warning Details Brain Infection and Viral Risks
Gazyva carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy, a rare and serious brain infection. The most common side effects observed in the primary membranous nephropathy trial were infusion-related reactions and upper respiratory tract infections. The regulatory agency granted the submission Breakthrough Therapy, Orphan Drug, and Priority Review designations.



